Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday

Adverum Biotechnologies (NASDAQ:ADVM) is projected to issue its quarterly earnings data before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter.

Adverum Biotechnologies Trading Up 2.4 %

ADVM stock opened at $4.61 on Friday. The company has a market cap of $95.90 million, a P/E ratio of -0.77 and a beta of 1.14. Adverum Biotechnologies has a 52 week low of $3.52 and a 52 week high of $18.00. The company’s 50-day moving average price is $4.38 and its 200 day moving average price is $5.90.

Analysts Set New Price Targets

ADVM has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Adverum Biotechnologies from a “hold” rating to a “sell” rating in a report on Thursday, December 19th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Adverum Biotechnologies in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $27.83.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.